Dianthus Therapeutics, Inc. (DNTH)

Over the past six months, Dianthus Therapeutics' shares have seen a substantial increase, rising by 110.7% since the start of 2026. In March 2026, the company announced an early "GO" decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19.4% surge in the stock price. In March 2026, Dianthus Therapeutics closed an upsized underwritten public offering, raising approximately $719 million in gross proceeds. On May 5, 2026, the company reported its financial results for the first quarter ending March 31, 2026, highlighting recent business achievements. Claseprubart was granted Orphan Drug Designation by the FDA for Myasthenia Gravis. In the past three months, Dianthus Therapeutics insiders sold $26,564,008.00 in company stock, with no insider buying reported. The company granted inducement equity awards to newly hired non-executive employees in May and April 2026. Successful Phase 2 "MaGic" trial data in generalized Myasthenia Gravis (gMG) in late 2025 contributed to a significant appreciation in the stock price over the preceding 12 months.

As a clinical-stage biotechnology company, Dianthus Therapeutics, Inc. does not currently have commercialized products or services with discernible demand seasonality. The company's focus is on advancing its clinical pipeline.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing complement therapeutics for severe autoimmune and inflammatory diseases. The company aims to design and deliver novel, monoclonal antibodies with enhanced selectivity and potency compared to existing complement therapies. Its major product candidates include DNTH103 (Claseprubart), a monoclonal antibody in Phase 2 and Phase 3 clinical trials for the treatment of generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP), and DNTH212, an early-stage bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Dianthus Therapeutics, Inc. is headquartered in New York, New York, and also has operations in Waltham, Massachusetts, United States. A significant portion of its institutional shareholders are based in the United States, with some also from the United Kingdom.

Dianthus Therapeutics generally holds a positive brand reputation, particularly within the investment and analyst community, with a consensus "Buy" rating from analysts. The early "GO" decision in the Phase 3 CAPTIVATE CIDP trial significantly boosted Wall Street optimism. There have been no widely reported events negatively impacting the company's overall brand reputation in the past year, although insider stock sales could be viewed with caution by some investors.

Approximately 47.53% of Dianthus Therapeutics, Inc.'s stock is held by institutions, while insiders hold 3.02%, and public companies and individual investors hold 69.89%. Major institutional owners include Fmr Llc, Wellington Management Group Llp, and Vanguard Group Inc. Key individual insiders who own company stock include Fairmount Funds Management Llc, Ryan Savitz, and Marino Garcia.